Drug Trial Radar · NCT07005336
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 9, 2025
Primary completion
Aug 30, 2026
Study completion Jan 9, 2029
Sponsor
- Lead sponsor
- TJ Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with sintilimab and chemotherapy versus sintilimab combined with chemotherapy in patients with previously untreated locally advanced unresectable or metastatic NSCLC who are not suitable for targeted therapies such as EGFR or ALK. Eligible subjects will be randomly assigned in a 1:1 ratio to receive either uliledlimab combined with sintilimab and chemotherapy or sintilimab combined with chemotherapy. Enrolled subjects will first enter a safety run-in period. When at least 12 subjects have been randomly assigned to Group A and have received ≥ 1 dose of study drug (with a total of approximately 24 subjects), enrollment will be suspended for safety evaluation. The safety evaluation period will last 3 weeks, during which safety, tolerability, and PK data of uliledlimab combined with sintilimab and chemotherapy will be collected and evaluated by the Safety Review Committee (SRC). The SRC will decide through discussion whether to proceed to the next stage of randomized enrollment, whether additional subjects need to be enrolled for safety evaluation, or whether the study treatment should be terminated due to high safety risks. After the SRC reaches a unanimous resolution, enrollment will continue until a total of approximately 150 subjects are enrolled. All 150 subjects will be included in the final efficacy analysis. If 3 or more subjects experience Grade ≥ 3 treatment-related AEs that are unrelieved and lead to discontinuation of all study drugs during the safety run-in period, enrollment in the next stage will be terminated.
Conditions
- Non Small Cell Lung Cancer
Interventions
UliledlimabDrug
30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,at most 35 cycles
SintilimabDrug
Intravenous infusion at a recommended dose of 200 mg once every 3 weeks,at most 35 cycles
PemetrexedDrug
Intravenously at a recommended dose of 500 mg/m2 body surface area (BSA) ,once every 3 weeks until the disease progresses.
GemcitabineDrug
1000 mg/m2, administered on Days 1 and 8 ,once every 3 weeks (Q3W) for 4 cycles
Cisplatin Or CarboplatinDrug
Cisplatin: 5 mg/m2 administered intravenously every 3-4 weeks for 4 cycles Carboplatin:75 mg/m2, administered intravenously every 3-4 weeks for 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From the date of randomization to the date of first documented disease progression (assessed by a blinded independent central review [BICR] according to RECIST v1.1) or death from any cause, whichever occurs first,assessed up to 6months.
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, China
Binzhou Medical University Hospital
Binzhou, China
Sichuan Cancer Hospital
Chengdu, China
Chongqing University Three Gorges Hospital
Chongqing, China
Harbin Medical University Cancer Hospital
Ha’erbin, China
Anhui Provincial Cancer Hospital
Hefei, China
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Jiangmen Central Hospital
Jiangmen, China
Yunan Cancer Hospital
Kunming, China
Linyi People's Hospital
Linyi, China
Lishui Central Hospital
Lishui, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Guangxi Medical University Cancer Hospital
Nanning, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
The Second People's Hospital of Neijiang
Neijiang, China
Shanghai Chest Hospital
Shanghai, China
First Hospital of Shanxi Medical University
Taiyuan, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Hubei Cancer Hospital
Wuhan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Xiangyang Central Hospital
Xiangyang, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
The Second People's Hospital of Yibin
Yibin, China
General Hospital of Ningxia Medical University
Yinchuan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Zhoukou Central Hospital
Zhoukou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.